VETERINARY TEAM REFERENCE

DEA & state schedules

Scheduling applies to the medication, not to the patient. This independent reference is not affiliated with the DEA.

Neomycin + polymyxin B + bacitracin (ophthalmic)

FEDERAL STATUS

Not federally scheduled

The identified ingredients in this entry are not listed in the reviewed federal schedules. Prescription-only status, product restrictions and state law are separate questions.

Federal source ↗

State / prescribing or dispensing jurisdiction

STATE STATUS

Select a jurisdiction

Choose the state relevant to prescribing or dispensing. Patient residence alone may not determine every applicable rule.

What each federal schedule means

Highlighted rows match the verified federal or selected state schedule. The schedule describes legal control and abuse potential; it does not rank clinical usefulness or establish a dose.

Federal Schedules I–V: meaning and practice implications
Schedule	Meaning and practice
I	High abuse potential; no currently accepted medical use in U.S. treatment; lacks accepted safety under medical supervision. In practice: Not available for routine veterinary prescribing. Authorized research is a separate pathway.
II	High abuse potential; accepted medical use, sometimes with severe restrictions; abuse can cause severe dependence. In practice: No prescription refills under federal law. Strict prescribing, security and record requirements apply.
III	Less abuse potential than I or II; accepted medical use; abuse can cause moderate or low physical dependence or high psychological dependence. In practice: Federal prescriptions allow up to five authorized refills within six months. State rules may be stricter.
IV	Lower abuse potential than III; accepted medical use; limited dependence risk relative to III. In practice: The same federal five-refill / six-month prescription limit applies. Controlled-drug handling still applies.
V	Lower abuse potential than IV; accepted medical use; limited dependence risk relative to IV. In practice: Still controlled. Check authorized refills and state limits; do not automatically apply the III–IV refill rule.

What this means for the chart

For a controlled medication, confirm the prescriber’s authority for the applicable schedule, the exact formulation and quantity, authorized refills, secure handling, and required inventory / dispensing records. Check the state’s veterinary rules and any prescription monitoring program (PDMP) requirements or exemptions.

A PDMP reporting requirement does not by itself make a drug scheduled. “Not federally scheduled” does not mean over the counter, risk-free, or exempt from state law. States may use additional categories, such as Schedule VI, outside the federal I–V system.

← Medication & Supplement Reference

VETERINARY TEAM REFERENCE · MEDICATION

Neomycin + polymyxin B + bacitracin (ophthalmic)

A three-antibiotic ophthalmic ointment for susceptible superficial bacterial eye infections. This combination contains bacitracin and no corticosteroid; veterinary eye examination determines its appropriate use.

Ophthalmic antibiotic combinationProduct-specific clinical reference

Updated October 16, 2026 · Sources and review status below

For veterinarians and veterinary staff. Product-label information is distinct from extra-label clinical practice. This is not a complete prescribing formulary or an automated interaction screen. Verify the current label, exact formulation, patient and species-specific clinical reference before use. Independent veterinary/pharmacy review remains pending.

Prescribing overview

Sterile triple-antibiotic eye ointment contains no corticosteroid.

Key prescribing checks

Neomycin can cause sensitization; worsening redness, swelling or failure to heal needs reassessment.
The label notes that ophthalmic ointments may retard corneal wound healing. Persistent eye pain or discharge requires examination, not indefinite refilling.

Uses by species

Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.

Veterinary patients

Not established by reviewed human label

Superficial bacterial eye infection: veterinary use needs an eye examination.

Animal use requires a veterinarian's separate diagnosis and prescription.

Use / indication source ↗

Pharmacology & pharmacokinetics

Mechanism and clinical role

Neomycin inhibits protein synthesis, polymyxin disrupts membranes, and bacitracin interferes with cell-wall synthesis.

Absorption, distribution, metabolism and elimination

Veterinary ocular/systemic kinetic values were not established in this label.

SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC

Contraindications & cautions

Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.

Neomycin + polymyxin B + bacitracin (ophthalmic)

Human sterile ophthalmic antibiotic ointment

Contraindications · when not to use

Hypersensitivity to any component.

Precautions & monitoring

Neomycin sensitization, delayed corneal healing, resistant/fungal overgrowth and container contamination require attention. Never inject into the eye.

Human label; this does not establish veterinary approval or an animal treatment protocol.

NeoPolyBac is ingredient shorthand; verify the actual dispensed product.

Safety sources checked: October 16, 2026. Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.

Adverse effects

Sensitization, delayed corneal healing and resistant or fungal overgrowth may occur.

These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.

Dosing & administration

Verify the source before prescribing. The regimens below summarize selected veterinary product labels, not every accepted veterinary use. They are not automatic substitutions between brands or formulations. Renal/hepatic disease, concurrent therapy, age, indication and clinical response can require a different plan.

A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.

A veterinary dose was not verified from an approved animal label; human dosing is not an animal regimen.

Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗

Drug & supplement interactions

This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.

A product-specific interaction summary has not been established here. An empty list must not be interpreted as “no interactions.” Review the full source and a species-appropriate clinical reference.

Monitoring

Reassess persistent pain, discharge or worsening redness.

Client counseling

Do not replace with a skin ointment; avoid contaminating the tip and never inject into the eye.

This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.

Storage & handling

Maintain sterility and follow the dispensed ophthalmic tube's storage instructions.

Brands, formulations & ingredient identity

Active ingredients

Neomycin sulfate · Polymyxin B sulfate · Bacitracin zinc

Other searchable names: NeoPolyBac · Neo Poly Bac · neomycin polymyxin bacitracin

NeoPolyBac is a shorthand ingredient description, not proof of one manufacturer or package.

This combination differs from NeoPolyGram and NeoPolyDex. The final ingredient must be confirmed from the container.

A skin triple-antibiotic ointment is not automatically a sterile ophthalmic substitute.

Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.

This entry is indexed by its generic ingredient name; verify the actual manufacturer and package.

References & review status

Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.

01DailyMed: neomycin-polymyxin-b-bacitracin-ophthalmic product labeling ↗

Search another medication or supplement →

Prescribing overview

Key prescribing checks

Uses by species

Veterinary patients

Pharmacology & pharmacokinetics

Mechanism and clinical role

Absorption, distribution, metabolism and elimination

Contraindications & cautions

Contraindications · when not to use

Precautions & monitoring

Adverse effects

Dosing & administration

Drug & supplement interactions

Monitoring

Client counseling

Storage & handling

Brands, formulations & ingredient identity

Active ingredients

Related ingredient combinations

References & review status

Related Resources